9/28/2023 0 Comments Simon med arrowhead![]() SimonMed Imaging is one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States. and its subsidiaries © 2023 Myriad Genetics, Inc. For more information, visit Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, M圜hoice CDx, Prequel, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. “With recent clinical guideline developments from a variety of professional societies regarding genetic risk assessment beginning as early as age 25-30, this collaboration is critically important to help recognize and screen younger high-risk patients and ensure they receive appropriate supplemental screening and medical management options to best manage their elevated risk.” ![]() ![]() Diaz, president and CEO, Myriad Genetics. “Myriad’s commitment to patient access, affordability, health equity and scientific innovation directly aligns with SimonMed’s mission to better serve our communities,” said Paul J. The program is expected to be operational in all 86 of SimonMed’s women’s imaging sites by the end of this year, with the goal of supporting all SimonMed patients in their remaining 85 sites and service lines, thereafter. Myriad and SimonMed will begin a phased rollout of the program in early May 2023 to patients at select SimonMed women’s imaging sites. John Simon, CEO of SimonMed and board-certified Radiologist. Early diagnosis through the newest diagnostic pathways leads to better outcomes: it saves lives,” said Dr. It is personalized healthcare designed so that patients and their providers will have a more accurate understanding of the cancer risk and can take precise action as needed from genetic screening to supplemental imaging like MRI and ultrasound. “This advanced technology platform was a collaboration between SimonMed and Myriad. The collaboration will bring together the strengths of Myriad’s risk assessment resources and hereditary cancer test, MyRisk with RiskScore, and SimonMed’s deep expertise in the medical imaging space. Leveraging a custom-built Myriad tool developed in collaboration with SimonMed, the program is expected to enable affordable access to genetic testing and deliver personalized insights to better inform clinical decisions for the millions of patients and families served at SimonMed.įor more than 30 years, Myriad and SimonMed have worked independently to help millions of patients understand their health and well-being through genetic testing and diagnostic imaging. ![]() SALT LAKE CITY, Ap(GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed ® Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk ® with RiskScore ® and patient education. New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |